Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer

Stopped early · Phase 1

Conditions studied: Colorectal Neoplasms

In brief

This study will evaluate the safety and tolerability of a personalized live, attenuated, double-deleted Listeria monocytogenes (pLADD) treatment in adults with metastatic colorectal cancer.

Key facts

Study ID

NCT03189030

Run by

Aduro Biotech, Inc.

People needed

28

Starts

2017-05-02

Expected to finish

2020-09-02

Last updated by the study team

2020-10-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• metastatic colorectal cancer (mCRC) that is microsatellite stable (MSS)
• able to provide adequate tumor tissue from at least 1 accessible tumor site
• completed or have developed intolerance to a course of oxaliplatin- or irinotecan-based frontline therapy at Screening
• on maintenance standard-of-care chemotherapies or on treatment holiday
• Eastern Cooperative Oncology Group (ECOG) 0 or 1
• adequate organ function
• progression of disease at the time of Enrollment

You may not qualify if…

• BRAF V600E mutation
• known allergy to both penicillin and sulfa drugs
• implanted devices that cannot be easily removed
• immunodeficiency, immune compromised state or receiving immunosuppressive therapy

Where it is running

• City of Hope National Medical Center — Duarte, California, United States
• University of California Los Angeles — Los Angeles, California, United States
• University of California Davis Comprehensive Cancer Center — Sacramento, California, United States
• Stanford — Stanford, California, United States
• Mary Crowley Cancer Research - Medical City — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.